Pharmaxis Announces Encouraging Results from Phase 1c Study of Topical Pan LOX Inhibitor in Established Skin Scars

News

23rd May 23

Release Date: 23/05/2023 4:34pm

Well tolerated with good safety profile
Marked change in scar composition with 30% reduction in collagen content
First ever proof that LOX inhibition reduces skin collagen underpins expansion of Pharmaxis and Professor Fiona Wood collaboration into new skin fibrosis indications
No overall improvements in scar appearance seen at 3 months points to need for longer study in established scars